Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

112.43 +1.03 (+0.92%)
Streaming Delayed Price Updated: 2:18 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,646,387
Open 111.64
Bid (Size) 112.42 (2)
Ask (Size) 112.44 (1)
Prev. Close 111.40
Today's Range 111.26 - 112.85
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.36%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals.
NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill

Performance

YTD
+15.7%
+15.7%
1 Month
+2.6%
+2.6%
3 Month
+14.3%
+14.3%
6 Month
-2.8%
-2.8%
1 Year
+17.3%
+17.3%

More News

Read More
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Is the Market Bullish or Bearish on Novartis?
Via Benzinga
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Via Benzinga
Exposures Product Safety
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Via Benzinga
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Via Investor's Business Daily
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction
Via Investor's Business Daily
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
Via Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Via Benzinga
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Via Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
Via Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Via The Motley Fool
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
Via Investor's Business Daily
Topics Earnings
Exposures Financial

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 112.43
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 03/28/25 02:18 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.